Significant Growth of our Betapol Business

Significant Growth of our Betapol Business

Significant Growth for our Betapol Business Our global business has grown significantly over the past year and we are looking forward to building further on this success. We are strengthening the organization supporting our nutrition activities, engaging in new scientific research programs, and bringing innovations to the market.

  • The business has been structured under a global business unit Human Nutrition headed by Stefan Thueringer who has been responsible for IOI Loders Croklaan’s infant nutrition business since 2012. Wiola Mi, holding a PhD in biomedical neuroscience and previously holding scientific management roles at Danone Nutricia Research Europe, Early Life Nutrition, Mead Johnson Europe, and GSK, is joining the team to drive our global science program and innovation agenda.
  • Our sales team is continuously growing globally and in China specifically with the region having shown and believed to continue to be our highest growth market.
  • We are especially excited and honored that we will work together with long-standing OPO authorities on a significant scientific research program. The aim of the program is to identify and substantiate new benefits of Betapol in infant nutrition which we will bring to our key partners for joiny studies and trials. We are fully committed to further extend the Betapol portfolio for infant nutrition and explore the possibilities of expanding into other key nutrition market segments.
  • Through the year we will showcase Betapol, OPO, and structured lipids developments at events and seminars and are looking forward to engage with our customers, partners, and scientific community and stakeholders.

We are happy to continue offering you world-class infant nutrition solutions that are founded in science